0 results available. Select is focused ,type to refine list, press Down to open the menu,
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, H...
The following section summarizes insights on Eli Lilly and Company's Revenue Growth:
We've identified the following companies as similar to Eli Lilly and Company because they operate in a related industry or sector. We also considered size, growth, and various financial metrics to narrow down the list to the ones listed below.
To view the full list of supported financial metrics please see Complete Metrics Listing.
Metrics similar to Revenue Growth in the growth category include:
Period over prior period growth in revenue.
The revenue growth measures a company’s revenue year-over-year growth. The formula to calculate revenue growth and an example calculation for Eli Lilly’s trailing twelve months is outlined below:
Revenue Growth = (Current Year - Prior Year) / ABS(Prior Year Revenue)*
32.0% = ($45.043 B - $34.124 B) / $34.124 B
*ABS = An absolute value adjustment is used to ensure the direction of growth of negative numbers is reflected
The tables below summarizes Eli Lilly’s performance over the last five years:
| Fiscal Year | Revenue | Growth |
|---|---|---|
| 2020-12-31 | 24.54 B | 9.9% |
| 2021-12-31 | 28.318 B | 15.4% |
| 2022-12-31 | 28.541 B | 0.8% |
| 2023-12-31 | 34.124 B | 19.6% |
| 2024-12-31 | 45.043 B | 32.0% |
The tables below summarizes Eli Lilly’s performance over the last four quarters:
| Quarter Ending | Revenue | Growth |
|---|---|---|
| 2024-03-31 | 8.768 B | 26.0% |
| 2024-06-30 | 11.303 B | 36.0% |
| 2024-09-30 | 11.439 B | 20.4% |
| 2024-12-31 | 13.533 B | 44.7% |
Growth calculations are always made in the company’s reporting currency to ensure currency fluctuations do not impact the calculation. Eli Lilly’s reports in the USD currency. You can read more about Revenue here.
The chart above depicts the distribution of revenue growth for companies operating in the Healthcare sector in the Developed economic region. Over 1,910 companies were considered in this analysis, and 1,838 had meaningful values. The average revenue growth of companies in the sector is 30.4% with a standard deviation of 122.9%.
Eli Lilly and Company's Revenue Growth of 32.0% ranks in the 79.3% percentile for the sector. The following table provides additional summary stats:
| Economic Risk Region | Developed |
| Total Constituents | 1,914 |
| Included Constituents | 1,838 |
| Min | -97.8% |
| Max | 1,439.6% |
| Median | 6.8% |
| Mean | 30.4% |
| Standard Deviation | 122.9% |
You can find companies with similar revenue growth using this stock screener.